firibastat

has antihypertensive activity; a dimer of EC33 with a disulfide linkage; structure in first source

Also Known As:

4,4'-dithio(bis(3-aminobutyl sulfonic acid)); RB 150; RB-150; RB150; RB150 cpd

Networked: 26 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Llorens-Cortes, Catherine: 14 articles (01/2022 - 05/2004)
2.	Marc, Yannick: 10 articles (01/2022 - 09/2008)
3.	Balavoine, Fabrice: 9 articles (01/2022 - 08/2012)
4.	De Mota, Nadia: 4 articles (01/2022 - 01/2019)
5.	Hmazzou, Reda: 4 articles (08/2021 - 01/2018)
6.	Keck, Mathilde: 3 articles (01/2022 - 01/2019)
7.	Roques, Bernard P: 3 articles (08/2012 - 05/2004)
8.	Agbulut, Onnik: 2 articles (01/2022 - 01/2019)
9.	Aronow, Wilbert S: 2 articles (01/2022 - 01/2020)
10.	Nesbitt, Shawna D: 2 articles (12/2021 - 01/2019)

Related Diseases

1.	Hypertension (High Blood Pressure) 12/24/2021 - "Firibastat: a Novel Treatment for Hypertension." 01/27/2022 - "The aim of this review is to investigate the current knowledge about firibastat in the treatment of hypertension." 01/27/2022 - "Current Knowledge about the New Drug Firibastat in Arterial Hypertension." 01/01/2022 - "Firibastat has the potential to be groundbreaking in the management of resistant hypertension." 12/24/2021 - "This review introduces firibastat as a new therapeutic class of treatment for hypertension focused on the renin angiotensin system in the brain. "
2.	Myocardial Infarction 03/01/2023 - "Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study." 03/01/2023 - "Preclinical data suggest that central renin-angiotensin system blockade by the brain aminopeptidase-A inhibitor firibastat can improve left ventricular ejection fraction (LVEF) after myocardial infarction (MI). " 01/01/2022 - "Blockade of brain renin-angiotensin system (RAS) overactivity by firibastat, the first centrally acting aminopeptidase A (APA) inhibitor prodrug, has already demonstrated its effectiveness in improving cardiac function after myocardial infarction (MI). " 01/01/2019 - "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI). "
3.	Heart Failure 01/01/2019 - "We hypothesized that orally administered firibastat (previously named RB150), an APA inhibitor prodrug, would attenuate heart failure (HF) development after MI in mice, by blocking brain RAS hyperactivity. " 01/01/2019 - "Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI). "
4.	Overweight 01/01/2019 - "Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins."
5.	Left Ventricular Dysfunction 03/01/2023 - "Firibastat was not superior to ramipril for prevention of left ventricular dysfunction after first acute anterior MI, and their safety profiles were similar. "

Related Drugs and Biologics

1.	Angiotensin Receptors (Angiotensin II Receptor)
2.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
3.	Glutamyl Aminopeptidase (Aspartyl Aminopeptidase)
4.	Prodrugs
5.	Ramipril (Altace)
6.	sacubitril and valsartan sodium hydrate drug combination
7.	Antihypertensive Agents (Antihypertensives)
8.	firibastat
9.	Salts
10.	Angiotensin III